Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives

Journal of Medicinal Chemistry

Volumn 45, Issue 25, 2002, Pages 5604-5606

  Seitz, Lainne E ^a   Suling, William J ^a   Reynolds, Robert C ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETOXYBENZYL 2 QUINOXALINECARBOXYLATE; CARBOXYLIC ACID DERIVATIVE; ESTER DERIVATIVE; PRODRUG; PYRAZINE; PYRAZINOIC ACID; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SYNTHESIS;

ANTI-BACTERIAL AGENTS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; PYRAZINES; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037028002     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020310n     Document Type: Article

References (22)

1. Duncan, K. The impact of genomics on the search for novel tuberculosis drugs. Novartis Found. Symp. 1998, 217, 228-237.
2. Cynamon, M. H.; Klemens, S. P.; Chou, T. S.; Gimi, R. H.; Welch, J. T. Antimycobacterial activity of a series of pyrazinoic acid esters. J. Med. Chem. 1992, 35, 1212-1215 and references therein.
3. Cynamon, M. H.; Gimi, R.; Gyenes, F.; Sharpe, C. A.; Bergmann, K. E.; Han, H.-J.; Gregor, L. B.; Rapolu, R.; Luciano, G.; Welch, J. T. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. J. Med. Chem. 1995, 38, 3902-3907 and references therein.
4. Maccari, R.; Ottana, R.; Monforte, F.; Vigorita, M. G. In vitro antimycobacterial activities of 2′-monosubstituted isonicotinoylhydrazides and their cyanoborane adducts. Antimicrob. Agents Chemother. 2002, 46 (2), 294-299 and references therein.
5. Georgieva, N.; Gadjeva, V. Isonicotinoylhydrazone analogues of isoniazid: Relationship between superoxide scavenging and tuberculostatic activities. Biochemistry (Moscow) 2002, 67 (5), 588-591 and references therein.
6. Reynolds, R. C.; Bansal, N.; Rose, J.; Friedrich, J.; Suling, W. J.; Maddry, J. A. Ethambutol-sugar hybrids as potential inhibitors of mycobacterial cell-wall biosynthesis. Carbohydr. Res. 1999, 317 (1-4), 164-179.
7. McDermott, W.; Tompsett, R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 1954, 70, 748-754.
8. Heifets, L. B.; Flory, M. A.; Lindholm-Levy, P. J. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against M. tuberculosis? Antimicrob. Agents Chemother. 1989, 33, 1252-1254.
9. Zimhony, O.; Cox, J. S.; Welch, J. T.; Vilcheze, C.; Jacobs, W. R. Pyrazinamide inhibits the eukaryotic-like fatty acid synthase I (FASI) of M. tuberculosis. Nat. Med. 2000, 6, 1043-1047.
10. Boshoff, H. I,; Mizrahi, V.; Barry, C. E. III Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthetase I. J. Bacteriol. 2002, 8, 2167-2172.
11. Scorpio, A.; Zhang, Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculosis drug pyrazinamide in tubercle bacillus. Nat. Med. 1996, 2, 662-667.
12. Reynolds, R. C.; Tiwari, A.; Harwell, J. E.; Gordon, D. G.; Garrett, B. D.; Gilbert, K. S.; Schmid, S. M.; Waud, W. R.; Struck, R. S. Synthesis and evaluation of several new (2-chloroethyl)-nitrosocarbamates as potential anticancer agents. J. Med. Chem. 2000, 43, 1484-1488.
13. Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Friedlos, F.; Martin, J.; Spooner, R.; Davies, L.; Marais, R.; Springer, C. J. Self-immolative nitrogen mustard prodrugs for suicide gene therapy. J. Med. Chem. 1998, 41, 5297-5309.
14. Steglich, W.; Neises, B. Simple method for the esterification of carboxylic acids. Angew. Chem., Int. Ed. Engl. 1978, 17, 522-524.
15. Yosioka, I.; Otomasu, H. Studies on phenazines. XV. The ring cleavage of phenazine. (1). 2,3-Quinoxalinedicarboxylic acid. Chem. Pharm. Bull. 1957, 5, 277-279.
16. Barry, C. E., III; Slayden, R. A.; Sampson, A. E.; Lee, R. E. Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem. Pharmacol. 2000, 59, 221-31.
17. Moriguchi, I.; Hirono, S.; Liu, Q.; Nakagome, I.; Hirano, H. Comparison of reliability of logP values for drugs calculated by several methods. Chem. Pharm. Bull. 1994, 42, 976-978 and references therein.
18. Denny, W. A. The role of hypoxia-activated prodrugs in cancer therapy. Lancet Oncol. 2000, 1 (1), 25-29.
19. Rosenkrands, I.; Slayden, R. A.; Crawford, J.; Aagaard, C.; Barry, C. E. III; Andersen, P. Hypoxic response of mycobacterium tuberculosis studied by labeling and proteome analysis of cellular and extracellular proteins. J. Bacteriol. 2002, 184, 3485-3491.
20. (a) Zhang, Z.; Hillas, P. J.; Ortiz de Montellano, P. R. Reduction of peroxides and dinitrobenzenes by mycobacterium tuberculosis thioredoxin and thioredoxin reductase. Arch. Biochem. Biophys. 1999, 363, 19-26.
21. Murugasu-Oei, B.; Dick, T. Bactericidal activity of nitrofurans against growing and dormant mycobacterium bovis BCG. J. Antimicrob. Chemother. 2000, 46, 917-919.
22. Flynn, J. L.; Chan, J. Minireview. Tuberculosis: Latency and reactivation. Infect. Immun. 2001, 69 (7), 4195-4201 and references therein.